BioHarvest Sciences Appoints New Head of Business Development for its CDMO Division
British Columbia and Rehovot, Israel--(Newsfile Corp. - May 13, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced the appointment of Nedira Salzman-Frenkel to Vice President of Business Development. Ms. Salzman-Frenkel's role will be instrumental for sourcing and managing new prospective contracts across the pharmaceutical, nutraceu
Biotechnology, Pharmaceuticals, Health
2026-05-13 5:32 PM EDT | BioHarvest Sciences Inc.
PharmaTher's Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus
Toronto, Ontario--(Newsfile Corp. - May 13, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a specialty pharmaceutical company, today announced that Sairiyo Therapeutics Inc. ("Sairiyo"), a company 49% owned by PharmaTher and 51% owned by PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF), is pursuing its strategic plans to focus on the clinical development of its patented enteric-coated oral Cepharanthine ("PD-001") as a potential therapeutic candidate
Biotechnology, Pharmaceuticals
2026-05-13 10:11 AM EDT | PharmaTher Holdings Ltd.
BetterLife Pharma Announces Appointment of Doug Drysdale as Executive Chairman and Director
Vancouver, British Columbia--(Newsfile Corp. - May 13, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biotech company, is pleased to announce it has appointed Doug Drysdale, currently BetterLife's corporate advisor and formerly CEO of Cybin Inc. ("Cybin") (NYSE: CYBN), as Executive Chairman and Director. At Cybin, Mr. Drysdale led the company's strategy and team build-out, taking it from molecule inception to Pha
2026-05-13 8:00 AM EDT | BetterLife Pharma Inc.
BioHarvest Sciences Announces Successful Completion of Stage 1 Development of Saffron Composition for Nutraceutical and Culinary Applications
- CDMO program advances to Stage 2 of development agreement valued at $1.125 million -Advancement of sustainable solution for the production of saffron, one of the world's most valuable and health-promoting botanicals - In addition to future commercial manufacturing royalties, BioHarvest also holds a 25% ownership position in Saffron Composition Vancouver, British Colum
Biotechnology, Pharmaceuticals, Health
2026-05-13 8:00 AM EDT | BioHarvest Sciences Inc.
PreveCeutical Closes Initial Tranche of Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - May 12, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical"), is pleased to announce that, further to its news release dated April 22, 2026, it has closed an initial tranche (the "Initial Tranche") of its previously announced $1,000,000 non-brokered private placement (the "Offering"), which Initial Tranche consisted of the issuance of 13,600,000 units (e
Biotechnology, Pharmaceuticals, Health
2026-05-12 5:02 PM EDT | PreveCeutical Medical Inc.
DIMERx Preclinical Data Confirms DMX-101 Non-Addictive Profile: No Reinforcement, No Dependence
San Francisco, California--(Newsfile Corp. - May 12, 2026) - DIMERx, Inc. ("DIMERx" or "the Company") is a clinical-stage biopharmaceutical company dedicated to addressing the public-health crisis of drug misuse and dependence, with a portfolio of first-
Biotechnology, Pharmaceuticals, Health
2026-05-12 9:00 AM EDT | DIMERx INC.
BioHarvest Sciences Signs $1.2M CDMO Stage 2 Contract for the Development of a Rare Fragrance Using Its Proprietary Botanical Synthesis Platform
British Columbia and Rehovot, Israel--(Newsfile Corp. - May 12, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that its CDMO division has s
Biotechnology, Pharmaceuticals, Health
2026-05-12 7:30 AM EDT | BioHarvest Sciences Inc.
Phio Pharmaceuticals Announces "Innovations in Skin Cancer Treatment and Prevention" in a Fireside Chat with Force Family Office on Tuesday, May 19, 2026
King of Prussia, Pennsylvania--(Newsfile Corp. - May 12, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing tec
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-05-12 7:00 AM EDT | Phio Pharmaceuticals Corp.
Herbal Dispatch Expands House of Brands Strategy with Launch of Northern Drip Extracts
Vancouver, British Columbia--(Newsfile Corp. - May 12, 2026) - Herbal Dispatch Inc. (CSE: HERB) (OTCQB: LUFFF) (FSE: HA9) ("Herbal Dispatch" or the "Company") is pleased to announce the launch of its new mid-to-premium cannabis extracts brand, Northern Drip, expanding the Company's presence in one of the fastest-growing segments of the Canadian cannabis market.Northern Drip represents Herbal Dispatch's fifth in-house brand launch, joining the Company
Pharmaceuticals, Cannabis, Cannabis Dispensary
2026-05-12 3:01 AM EDT | Herbal Dispatch Inc.
Telescope Innovations Shares Spring 2026 Conference and Events Lineup
Vancouver, British Columbia--(Newsfile Corp. - May 11, 2026) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) ("Telescope" or the "Company") is a developer of enabling technologies and services for the global pharmaceutical and high value chemical industries. The Company is pleased to report on outreach, marketing, and educational activities, both past and planned for spring 2026. Our participation includes presentations, exhibitions and keynote lect
Technology, Chemical, Pharmaceuticals
2026-05-11 8:00 AM EDT | Telescope Innovations Corp.
Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
Encinitas, California--(Newsfile Corp. - May 8, 2026) - Kiora Pharmaceuticals (NASDAQ: KPRX) today reported financial results for the first quarter ended March 31, 2026, and provided an update on its clinical pipeline of small molecules for the treatment of retinal diseases. First Quarter 2026 and Recent Highlights Enrollment in the Phase 2 ABACUS-2 study of KIO-301 remains very active, with expansion of clinical trial sites to accommodat
Biotechnology, Pharmaceuticals
2026-05-08 7:00 AM EDT | Kiora Pharmaceuticals, Inc.
Phio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update
King of Prussia, Pennsylvania--(Newsfile Corp. - May 7, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio today reported its financial results for the quarter ended March 31, 2026, and provided a busine
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-05-07 4:05 PM EDT | Phio Pharmaceuticals Corp.
Herbal Dispatch Reports Accelerating Veteran Customer Growth and Expansion of Insurance-Focused Service Channel
Vancouver, British Columbia--(Newsfile Corp. - May 7, 2026) - Herbal Dispatch Inc. (CSE: HERB) (OTCQB: LUFFF) (FSE: HA9) ("Herbal Dispatch" or the "Company"), is pleased to provide an update on the continued growth and expansion of its veteran-focused medical cannabis channel. The Company has experienced sustained acceleration in veteran customer acquisition, driven by targeted outreach, streamlined onboarding, and a dedicated service model tailored to the
Pharmaceuticals, Cannabis, Cannabis Dispensary
2026-05-07 7:00 AM EDT | Herbal Dispatch Inc.
InMed Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update
Vancouver, British Columbia--(Newsfile Corp. - May 6, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today reports financial results for the third quarter of the fiscal year 2026 which ended March 31, 2026. The Company's full financial statements and related MD&A for the third
Biotechnology, Pharmaceuticals
2026-05-06 6:00 PM EDT | InMed Pharmaceuticals
Nextleaf Reports AGM Results and Expands Industry Leadership Through CCBC
Vancouver, British Columbia--(Newsfile Corp. - May 6, 2026) - Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) ("Nextleaf", "OILS", or the "Company"), a multi-patented life science company and Canadian cannabis processor announces the results of its annual general meeting of shareholders (the "Meeting") held on April 30, 2026, in Vancouver, British Columbia, and provides an update on its continued engagement in industry advocacy initiatives supporting the advancement of B
Biotechnology, Pharmaceuticals, Cannabis, Cannabis Extractor
2026-05-06 9:00 AM EDT | Nextleaf Solutions Ltd.
Theralase(R) Announces $4 Million Brokered LIFE Offering
Toronto, Ontario--(Newsfile Corp. - May 5, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and v
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-05-05 7:10 PM EDT | Theralase Technologies Inc.
Herbal Dispatch Launches Next-Generation E-Commerce Platform, Targeting High-Growth $245 Million Insured Medical Cannabis Segment
Vancouver, British Columbia--(Newsfile Corp. - May 5, 2026) - Herbal Dispatch Inc. (CSE: HERB) (OTCQB: LUFFF) (FSE: HA9) ("Herbal Dispatch" or the "Company"), a cannabis e-commerce and distribution platform, is pleased to announce the launch of the upgraded HeroDispatch.com, alongside significant enhancements to HerbalDispatch.com for standard medical patients. These upgraded platforms are designed to position Herbal Dispatch as a preferred partner for bot
Pharmaceuticals, Cannabis, Cannabis Dispensary
2026-05-05 3:01 AM EDT | Herbal Dispatch Inc.
Bachem Announces Changes to the Corporate Executive Committee
Bubendorf, Switzerland--(Newsfile Corp. - May 5, 2026) - Bachem Holding AG (SIX: BANB) (“Bachem”) today announced that Torsten Wöhr, Chief Commercial Officer, has decided to pursue a new opportunity outside the company. Until a successor will be appointed, Anne-Kathrin Stoller will assume the role of Chief Commercial Officer in addition to her responsibilities as Chief Executive Officer (CEO), effective May 25, 2026. “Torsten Wöhr
Biotechnology, Chemical, Healthcare and Hospitals, Pharmaceuticals
2026-05-05 1:08 AM EDT | Bachem Holding AG
Theralase(R) Releases 2025 Annual Financial Statements and Provides Clinical Study Update
Toronto, Ontario--(Newsfile Corp. - May 4, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of various cancer, bacteria and viruses has released the Company's audited consolidated financial statements for the twelve-month period ended December 31
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-05-04 5:22 PM EDT | Theralase Technologies Inc.
Richards Group Inc. Announces 2026 First Quarter Results
Toronto, Ontario--(Newsfile Corp. - May 4, 2026) - Richards Group Inc. (TSX: RIC) (the "Company") announced today results for the quarter ended March 31, 2026. "The first quarter of 2026 saw a few important milestones in our long-term strategic plan. We launched a series of new OEM products under the DermapenWorld brand, grew significantly across our healthcare distribution verticals, and continued packaging modernization with ecommerce fulfillment site launches and the go-live of
Healthcare and Hospitals, Household / Consumer / Cosmetics, Pharmaceuticals
2026-05-04 7:00 AM EDT | Richards Group Inc.